Specifically, it has been demonstrated that the conditional deletion of genes involved in type I IFN receptor (IFNR) signalling in the CD8α+ DC compartment significantly affects CD8+ T-cell priming and tumour rejection [29–31], thus ascribing to CD8α+ DCs a crucial role in anti-tumour immunity (figure 1b). Here, IFNAR2 is linked to neoplasm.